154 related articles for article (PubMed ID: 26941365)
1. Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.
Penney KL; Pettersson A; Shui IM; Graff RE; Kraft P; Lis RT; Sesso HD; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2016 May; 25(5):745-9. PubMed ID: 26941365
[TBL] [Abstract][Full Text] [Related]
2. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.
Ma C; Wang X; Dai JY; Turman C; Kraft P; Stopsack KH; Loda M; Pettersson A; Mucci LA; Stanford JL; Penney KL
Cancer Epidemiol Biomarkers Prev; 2023 Oct; 32(10):1436-1443. PubMed ID: 37555839
[TBL] [Abstract][Full Text] [Related]
3. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
Luedeke M; Rinckleb AE; FitzGerald LM; Geybels MS; Schleutker J; Eeles RA; Teixeira MR; Cannon-Albright L; Ostrander EA; Weikert S; Herkommer K; Wahlfors T; Visakorpi T; Leinonen KA; Tammela TLJ; Cooper CS; Kote-Jarai Z; Edwards S; Goh CL; McCarthy F; Parker C; Flohr P; Paulo P; Jerónimo C; Henrique R; Krause H; Wach S; Lieb V; Rau TT; Vogel W; Kuefer R; Hofer MD; Perner S; Rubin MA; Agarwal AM; Easton DF; Al Olama AA; Benlloch S; ; Hoegel J; Stanford JL; Maier C
Hum Mol Genet; 2016 Dec; 25(24):5490-5499. PubMed ID: 27798103
[TBL] [Abstract][Full Text] [Related]
5. Height, Obesity, and the Risk of
Graff RE; Ahearn TU; Pettersson A; Ebot EM; Gerke T; Penney KL; Wilson KM; Markt SC; Pernar CH; Gonzalez-Feliciano AG; Song M; Lis RT; Schmidt DR; Vander Heiden MG; Fiorentino M; Giovannucci EL; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):193-200. PubMed ID: 29167279
[No Abstract] [Full Text] [Related]
6. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
7. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
Graff RE; Judson G; Ahearn TU; Fiorentino M; Loda M; Giovannucci EL; Mucci LA; Pettersson A
Prostate; 2017 May; 77(6):647-653. PubMed ID: 28102015
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
10. Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.
Graff RE; Meisner A; Ahearn TU; Fiorentino M; Loda M; Giovannucci EL; Mucci LA; Pettersson A
Br J Cancer; 2016 Apr; 114(8):939-44. PubMed ID: 26986253
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study of Aspirin Use and Prostate Cancer Risk by
Stopsack KH; Gonzalez-Feliciano AG; Peisch SF; Downer MK; Gage RA; Finn S; Lis RT; Graff RE; Pettersson A; Pernar CH; Loda M; Kantoff PW; Ahearn TU; Mucci LA;
Cancer Epidemiol Biomarkers Prev; 2018 Oct; 27(10):1231-1233. PubMed ID: 30108097
[No Abstract] [Full Text] [Related]
12. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
13. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA
Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811
[TBL] [Abstract][Full Text] [Related]
16. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.
Krstanoski Z; Vokac NK; Zagorac A; Pospihalj B; Munda M; Dzeroski S; Golouh R
BMC Urol; 2016 Jul; 16(1):35. PubMed ID: 27377958
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
